FDA to consider new evidence, risks behind fecal matter transplants

FDA to consider new evidence, risks behind fecal matter transplants

STAT Plus: FDA to consider new evidence, risks behind fecal matter transplants for C. diff treatment

By KATE SHERIDAN

STEVEN SENNE/AP

On Monday, the Food and Drug Administration will host its first formal discussion about fecal microbiome transplants in years.

READ MORE